Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Eileen Mary O'Reilly

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8076-9199; OpenAlex author ID A5076438320, A5158561853; NIH RePORTER profile ID 10379464. Sources: ClinicalTrials.gov.

Their work

Papers
205 (first author 30, last author 64)
Trials
10 (principal investigator on 9)
Grants
1
Labs led
1
Collaborators
565
Papers, trials and grants by year

2003: 1 trial · 2004: 1 trial · 2005: none · 2006: 1 trial · 2007: 1 trial · 2008: none · 2009: none · 2010: 1 trial · 2011: 6 papers · 2012: 11 papers, 2 trials · 2013: 4 papers · 2014: 4 papers · 2015: 6 papers · 2016: 11 papers · 2017: 13 papers · 2018: 14 papers, 1 trial · 2019: 11 papers · 2020: 16 papers, 1 trial · 2021: 12 papers · 2022: 13 papers, 1 trial · 2023: 15 papers · 2024: 14 papers · 2025: 17 papers · 2026: 38 papers, 1 grant

Papers 50 of 205

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.70136↗
  3. Pancreatic Cancer-Advances in the Last 50 Years. Co-author DOI 10.1002/wjs.70309↗
  4. Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here. Last author DOI 10.1007/s40265-026-02295-0↗
  5. ESMO podcast on upper GI cancers: highlights in hepatocellular carcinoma and pancreatic cancer from ESMO 2025. Last author DOI 10.1016/j.esmogo.2025.100277↗
  6. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  7. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  8. Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model. Co-author DOI 10.1016/j.jvir.2025.107908↗
  9. Precision Oncology in Pancreatic Cancer and Future Treatment Directions. First author DOI 10.1016/j.soc.2025.03.002↗
  10. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  11. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  12. Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms. Co-author DOI 10.1038/s41575-025-01170-9↗
  13. Genomic evolution of pancreatic cancer at single-cell resolution. Co-author DOI 10.1038/s41588-025-02468-9↗
  14. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Last author DOI 10.1038/s41591-026-04283-z↗
  15. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Last author DOI 10.1038/s41591-026-04299-5↗
  16. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Last author DOI 10.1038/s41591-026-04734-7↗
  17. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. Co-author DOI 10.1056/nejmc2611022↗
  18. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  19. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Co-author DOI 10.1080/14796694.2026.2664776↗
  20. NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer. Last author DOI 10.1093/jnci/djaf361↗
  21. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  22. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Last author DOI 10.1093/oncolo/oyag023↗
  23. Rethinking Radiation Therapy in the Era of RAS Inhibition for Pancreatic Cancer. First author DOI 10.1093/oncolo/oyag433↗
  24. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
  25. Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1117↗
  26. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-25-3189↗
  27. Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0772↗
  28. Pancreatic Cancer: Translating Tumor Biology into Actionability. Last author DOI 10.1158/2159-8290.cd-25-2014↗
  29. Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Do… Co-author DOI 10.1200/op-25-01431↗
  30. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  31. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  32. Pancreatic cancer: The RAS paradigm shift. First author DOI 10.1371/journal.pmed.1005283↗
  33. Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer. Co-author DOI 10.3389/fonc.2026.1762867↗
  34. Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers18020273↗
  35. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Last author DOI 10.64898/2026.03.15.711961↗
  36. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  37. Neoadjuvant chemotherapy induces transient, regimen-specific immune–stromal reprogramming in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.09.07.749769↗
  38. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  39. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  40. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  41. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.70088↗
  42. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  43. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Last author DOI 10.1016/j.xcrm.2025.102407↗
  44. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  45. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Last author DOI 10.1038/s41591-024-03362-3↗
  46. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Last author DOI 10.1080/14796694.2025.2458458↗
  47. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  48. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Last author DOI 10.1093/jnci/djae269↗
  49. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Last author DOI 10.1093/jnci/djaf139↗
  50. The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions. Co-author DOI 10.1158/2767-9764.crc-24-0167↗

Trials 10

  1. Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Principal investigator NCT05642962↗
  2. Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer Principal investigator NCT03245541↗
  3. A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT01676259↗
  4. Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Principal investigator NCT01585805↗
  5. A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Principal investigator NCT01647828↗
  6. Cardiopulmonary Resuscitation (CPR) Video to Enhance Advance Care Planning in Advanced Upper Gastrointestinal Cancer Patients Principal investigator NCT01105806↗
  7. Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery Principal investigator NCT00536874↗
  8. Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer Principal investigator NCT00331682↗
  9. S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Study chair NCT00075686↗
  10. Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer Principal investigator NCT00063947↗

Grants 1

  1. Biostatistics Core P50CA257881↗

Closest collaborators

The 25 strongest of 565 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wungki Park · 31 shared papers, 2019–2026 · strength 6.00
  2. Alice Chia-Chi Wei · 26 shared papers, 1 shared grant, 2019–2026 · strength 5.29
  3. Kenneth H. Yu · 44 shared papers, 2011–2026 · strength 5.11
  4. Christine A. Iacobuzio–Donahue · 24 shared papers, 1 shared grant, 2015–2026 · strength 4.10
  5. Anna M. Varghese · 29 shared papers, 2016–2026 · strength 3.97
  6. Zev A. Wainberg · 15 shared papers, 2021–2026 · strength 3.40
  7. Marinela Capanu · 20 shared papers, 1 shared grant, 2011–2026 · strength 3.07
  8. William R. Jarnagin · 23 shared papers, 2012–2026 · strength 2.91
  9. Matthew H. G. Katz · 14 shared papers, 2017–2026 · strength 2.80
  10. Vinod P. Balachandran · 13 shared papers, 1 shared grant, 2017–2026 · strength 2.64
  11. Christopher H. Crane · 17 shared papers, 2016–2026 · strength 2.55
  12. Marsha Reyngold · 13 shared papers, 2017–2026 · strength 2.25
  13. Teresa Mercade Macarulla · 15 shared papers, 2013–2026 · strength 2.15
  14. Kevin C. Soares · 12 shared papers, 2021–2026 · strength 2.14
  15. Olca Baştürk · 10 shared papers, 1 shared grant, 2017–2026 · strength 2.04
  16. Jeffrey A. Drebin · 13 shared papers, 2020–2026 · strength 1.97
  17. Bas Groot Koerkamp · 10 shared papers, 2020–2026 · strength 1.91
  18. Michael Ian D'Angelica · 15 shared papers, 2012–2026 · strength 1.90
  19. Marc G. Besselink · 10 shared papers, 2018–2026 · strength 1.80
  20. Maeve Aine Lowery · 29 shared papers, 2011–2020 · strength 1.77
  21. Shubham Pant · 10 shared papers, 2014–2026 · strength 1.75
  22. Fergus Keane · 8 shared papers, 2022–2026 · strength 1.65
  23. Andrew H. Ko · 11 shared papers, 2017–2026 · strength 1.62
  24. Brian Matthew Wolpin · 10 shared papers, 2013–2026 · strength 1.60
  25. Fiyinfolu O. Balogun · 8 shared papers, 2024–2026 · strength 1.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.